Galera Therapeutics Financing
Galera Therapeutics, Inc., Corporation just had published form D regarding $15.00 million equity financing. This is a new filing. Galera Therapeutics was able to finance itself with $15.00 million. That is 100.00% of the round of financing. The total private financing amount was $15.00 million. The private financing document was filed on 2016-11-28. The reason for the financing was: unspecified.
Galera Therapeutics is based in Pennsylvania. The firm’s business is Pharmaceuticals. The form was submitted by J Mel Sorensen Chief Executive Officer. The company was incorporated in 2012. The filler’s address is: 2 West Liberty Boulevard, Suite 110, Malvern, Pa, Pennsylvania, 19355. J. Mel Sorensen is the related person in the form and it has address: C/O Galera Therapeutics Inc., 2 West Liberty Boulevard, Suite 110, Malvern, Pa, Pennsylvania, 19355. Link to Galera Therapeutics Filing: 000095013816001481.
Analysis of Galera Therapeutics Offering
On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Galera Therapeutics sold 100.00% of the offering. Could this mean that the trust in Galera Therapeutics is high? The average investment floor size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 2,597.84% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this financing was set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Galera Therapeutics Also
The Form D signed by J Mel Sorensen might help Galera Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.